Leflunomide Medac (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for de novo pyrimidine synthesis. By limiting pyrimidine production, the drug reduces the proliferation of activated lymphocytes, thereby dampening the immune response that drives joint inflammation in rheumatoid and psoriatic arthritis.

The specific dosage of Leflunomide Medac is determined by the prescribing physician based on the individual’s clinical condition, disease severity, and laboratory monitoring. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Leflunomide is classified as pregnancy category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with conventional DMARDs such as methotrexate, Leflunomide offers a distinct mechanism by inhibiting pyrimidine synthesis rather than folate metabolism. It may be chosen when patients cannot tolerate methotrexate or need an alternative oral agent, but clinicians consider efficacy, safety profile, and potential drug interactions when selecting therapy.

Leflunomide Medac should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and store them out of reach of children.

Leflunomide Medac is taken orally, usually as a tablet swallowed with water. The exact timing (e.g., with or without food) should follow the prescribing physician’s guidance, and patients should adhere to the prescribed dosing schedule.

The most serious risks include severe liver injury, life‑threatening infections, interstitial lung disease, bone‑marrow suppression, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Regular monitoring of liver enzymes, blood counts, and pulmonary function is essential to detect these complications early.

Leflunomide should not be used by pregnant women, individuals with severe liver disease, uncontrolled hypertension, active serious infections, or those with known hypersensitivity to the drug. It is also contraindicated in patients planning pregnancy unless a thorough washout procedure is completed under medical supervision.